Varipulse, MedTech and Johnson & Johnson

Johnson & Johnson’s JNJ MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to ...
The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.
The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.
Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of ...
After a busy 2024, experts called out competition in soft tissue robotics, uncertainty from a Trump White House and continued ...
As a wave of volatility has been re-introduced to the system, investors are flocking toward blue-chip companies for stability ...